Non-melanoma skin cancer (NMSC), which includes basal cell (BCC) and cutaneous squamous cell (cSCC) carcinomas in its structure, is the leading among malignant skin tumors (MST). Among the measures for the prevention of invasive forms of MST, the detection and treatment of early forms, which for cSCC include actinic keratosis (AK) and Bowen’s disease (BD) can be mentioned. The use of topical drugs is an alternative method in case of impossibility of surgical removal and radiation therapy of MST for the treatment of AK in the presence of «carcerization fields» and location in esthetically demanding areas. According to the literature, the use of diglycidyl methylphosphonate ointment gives a clinical positive effect in the treatment of MST. A series of cases of diglycidyl methylphosphonate drug use for the treatment of AK, BD and BCC under the control of dermatoscopy is described.

OBJECTIVE

To determine the effectiveness of the diglycidyl methylphosphonate ointment application for the treatment of AK, BD and BCC with low risk of recurrence in the presence of contraindications or patient’s refusal from treatment by method of choice in accordance with the current clinical guidelines under the control of dermatoscopy.

MATERIAL AND METHODS

The study was conducted on the basis of the PRMU’s center of diagnosis and treatment of skin tumors. Dynamic clinical and dermatoscopic changes of 5 elements of AK, 3 elements of BD and 1 element of BCC on the therapy with diglycidyl methylphosphonate ointment are described.

RESULTS

The use of diglycidyl methylphosphonate ointment for the treatment of AK, BD and BCC elements has shown good clinical and cosmetic results.

CONCLUSION

Dermatoscopy is an additional objective method of evaluating the effectiveness of AK, BD and BCC topical therapy. Dynamic monitoring for residual dermatoscopic signs is recommended in case of pronounced clinical effect from the diglycidyl methylphosphonate ointment use for the treatment of AK and BD.